Description: Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Home Page: www.fulcrumtx.com
FULC Technical Analysis
26 Landsdowne Street
Cambridge,
MA
02139
United States
Phone:
617 651 8851
Officers
| Name | Title |
|---|---|
| Mr. Bryan E. Stuart | Pres, CEO & Director |
| Dr. Judith A. Dunn Ph.D. | Interim Chief Medical Officer |
| Dr. Bradley E. Bernstein M.D., Ph.D. | Founder |
| Dr. Michael R. Green | Founder |
| Dr. Rudolf Jaenisch M.D., Ph.D. | Founder |
| Prof. Jeannie T. Lee M.D., Ph.D. | Founder |
| Dr. Danny Reinberg | Founder |
| Ms. Esther P. Rajavelu | CFO & Treasurer |
| Mr. Mel Hayes | Chief Operating Officer |
| Mr. Gregory Tourangeau | Controller & Principal Accounting Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2789 |
| Price-to-Sales TTM: | 26.6208 |
| IPO Date: | 2019-07-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 104 |